Detalhe da pesquisa
1.
Immunogenicity and Safety of the Adjuvanted Recombinant Zoster Vaccine in Chronically Immunosuppressed Adults Following Renal Transplant: A Phase 3, Randomized Clinical Trial.
Clin Infect Dis;
70(2): 181-190, 2020 01 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30843046
2.
Recombinant Zoster Vaccine Significantly Reduces the Impact on Quality of Life Caused by Herpes Zoster in Adult Autologous Hematopoietic Stem Cell Transplant Recipients: A Randomized Placebo-Controlled Trial (ZOE-HSCT).
Biol Blood Marrow Transplant;
25(12): 2474-2481, 2019 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31394276
3.
Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with solid tumors, vaccinated before or during chemotherapy: A randomized trial.
Cancer;
125(8): 1301-1312, 2019 04 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30707761
4.
Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older.
N Engl J Med;
375(11): 1019-32, 2016 Sep 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27626517
5.
Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation: A Randomized Clinical Trial.
JAMA;
322(2): 123-133, 2019 07 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31287523
6.
Immunogenicity and Safety of the HZ/su Adjuvanted Herpes Zoster Subunit Vaccine in Adults Previously Vaccinated With a Live Attenuated Herpes Zoster Vaccine.
J Infect Dis;
216(11): 1343-1351, 2017 12 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29029122
7.
Immunogenicity and Safety of an Adjuvanted Herpes Zoster Subunit Vaccine Coadministered With Seasonal Influenza Vaccine in Adults Aged 50 Years or Older.
J Infect Dis;
216(11): 1352-1361, 2017 12 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29029224
8.
A multi-criteria decision making approach to identify a vaccine formulation.
J Biopharm Stat;
26(2): 352-64, 2016.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25616785
9.
Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1/2a randomized, placebo-controlled study.
J Infect Dis;
211(8): 1279-87, 2015 Apr 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25371534
10.
Respiratory syncytial virus and other respiratory viral infections in older adults with moderate to severe influenza-like illness.
J Infect Dis;
209(12): 1873-81, 2014 Jun 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-24482398
11.
Superior antigen-specific CD4+ T-cell response with AS03-adjuvantation of a trivalent influenza vaccine in a randomised trial of adults aged 65 and older.
BMC Infect Dis;
14: 425, 2014 Jul 30.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25078387
12.
Innate Responses to the Former COVID-19 Vaccine Candidate CVnCoV and Their Relation to Reactogenicity and Adaptive Immunogenicity.
Vaccines (Basel);
12(4)2024 Apr 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38675770
13.
Selection of an adjuvant for seasonal influenza vaccine in elderly people: modelling immunogenicity from a randomized trial.
BMC Infect Dis;
13: 348, 2013 Jul 26.
Artigo
em Inglês
| MEDLINE
| ID: mdl-23890405
14.
Corrigendum to "Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study" [Vaccine: X 11 (2022) 100189].
Vaccine X;
14: 100307, 2023 Aug.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37131960
15.
A Third Dose of the COVID-19 Vaccine, CVnCoV, Increased the Neutralizing Activity against the SARS-CoV-2 Wild-Type and Delta Variant.
Vaccines (Basel);
10(4)2022 Mar 25.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35455257
16.
Comparative immunogenicity of an mRNA/LNP and a DNA vaccine targeting HIV gag conserved elements in macaques.
Front Immunol;
13: 945706, 2022.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35935984
17.
Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study.
Vaccine X;
11: 100189, 2022 Aug.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35791320
18.
Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial.
Lancet Infect Dis;
22(3): 329-340, 2022 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34826381
19.
Proof-of-concept of a low-dose unmodified mRNA-based rabies vaccine formulated with lipid nanoparticles in human volunteers: A phase 1 trial.
Vaccine;
39(8): 1310-1318, 2021 02 22.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33487468
20.
Impact of Reactogenicity After Two Doses of Recombinant Zoster Vaccine Upon Physical Functioning and Quality of Life: An Open Phase III Trial in Older Adults.
J Gerontol A Biol Sci Med Sci;
76(3): 485-490, 2021 02 25.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32530462